Mallinckrodt has received subpoenas from both the Securities and Exchange Commission and the U.S. Attorney’s office in Massachusetts in recent months, according to an SEC filing.
In January, the company received a subpoena from the SEC for documents related to the sales, profits, promotion and pricing of Acthar, the company’s top-selling drug.
In December, Mallinckrodt received a subpoena from the U.S. Attorney’s Office for the District of Massachusetts for documents related to the company’s patient assistance programs.
Both subpoenas were disclosed in an SEC filing Tuesday. Mallinckrodt said in the filing that it was in the process of responding to each of the subpoenas and intended “to cooperate fully in each such investigation.”
Mark Trudeau, president and CEO of Mallinckrodt, mentioned the subpoenas in a Tuesday conference call with investors, pointing out that the U.S. Attorney in Massachusetts has issued subpoenas to a number of pharmaceutical companies over the last several quarters in regard to patient assistance programs.
Read more: St. Louis Business Journal